Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Clarity Wealth Advisors LLC

Posted by Defense World Staff on May 6th, 2023

Clarity Wealth Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,389 shares of the company’s stock after acquiring an additional 194 shares during the period. Johnson & Johnson accounts for about 2.1% of Clarity Wealth Advisors LLC’s investment portfolio, making the stock its 17th biggest holding. Clarity Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,602,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Glassy Mountain Advisors Inc. acquired a new position in Johnson & Johnson during the 4th quarter valued at about $35,000. Retirement Financial Solutions LLC bought a new position in Johnson & Johnson in the 4th quarter worth approximately $40,000. TD Capital Management LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $48,000. VitalStone Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $52,000. Finally, Iron Horse Wealth Management LLC raised its stake in shares of Johnson & Johnson by 112.8% during the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of research analyst reports. Atlantic Securities reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Guggenheim initiated coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Piper Sandler cut their price objective on Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. Finally, UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $173.00.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $162.68 on Friday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35. The company has a quick ratio of 0.77, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The stock has a market cap of $422.76 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. The business has a fifty day simple moving average of $158.33 and a 200-day simple moving average of $166.96.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the company posted $2.67 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.93%. Johnson & Johnson’s dividend payout ratio is presently 94.56%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.